(Q46885971)

26 December 2017

title

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. (English)

1 reference

26 December 2017

author name string

Holly E Careskey

1

1 reference

26 December 2017

R Aleks Davis

2

1 reference

26 December 2017

William E Alborn

3

1 reference

26 December 2017

Jason S Troutt

4

1 reference

26 December 2017

Guoqing Cao

5

1 reference

26 December 2017

Robert J Konrad

6

1 reference

26 December 2017

publication date

21 November 2007

1 reference

26 December 2017

Journal of Lipid Research

published in

1 reference

26 December 2017

volume

49

1 reference

26 December 2017

issue

2

1 reference

26 December 2017

page(s)

394-398

1 reference

26 December 2017

Molecular biology of PCSK9: its role in LDL metabolism

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

The proprotein convertases and their implication in sterol and/or lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

PCSK9: a promising therapeutic target for dyslipidemias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M700437-JLR200

10.1194/JLR.M700437-JLR200

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017